Human B7-1 No cross-reactivity in ELISA with
Human cell lysate (293 cell line)
Recombinant Human CD80 / B7-1 Protein (Catalog#10698-H08H)
This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human CD80 / B7-1 (rh CD80 / B7-1; Catalog#10698-H08H; Met 1-Asn 242; NP_005182.1). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
Monoclonal Mouse IgG1 Clone #01
0.2 μm filtered solution in PBS
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles.
Anti-B7-1 Antibody (Mouse Monoclonal 抗体) 经验证的应用
Please Note: Optimal concentrations/dilutions should be determined by the end user.
Anti-B7-1 Antibody (Mouse Monoclonal 抗体) 图片
Flow cytometric analysis of Human B7-1(CD80) expression on Daudi cells. Cells were stained with purified anti-Human B7-1(CD80), then a FITC-conjugated second step antibody. The histogram were derived from gated events with the forward and side light-scatter characteristics of intact cells.
The B-lymphocyte activation antigen B7-1 (referred to as B7), also known as CD8, is a member of cell surface immunoglobulin superfamily and is expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. As costimulatory ligands, B7-1 which exists predominantly as dimer and the related protein B7-2, interact with the costimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells, and thus constitute one of the dominant pathways that regulate T cell activation and tolerance, cytokine production, and the generation of CTL. The B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses. CD8 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.